Asian Medical Industries
Asian Medical Industries

Author: Stephan Kloos

Publisher: Routledge

Published: 2022-02-28

Total Pages: 329

ISBN-13: 1000523268

DOWNLOAD EBOOK

This book develops the concept of Asian Medical Industries as a novel perspective on traditional Asian medicines. Complementing and updating existing work in this field, the book provides a critical and comparative analytic framework for understanding Chinese Medicine, Ayurveda, Sowa Rigpa, and Japanese Kampo in the 21st century. No longer subaltern health resources or conservative systems of traditional knowledge, these medicines have become an integral part of modern Asia as innovative, lucrative industries. Ten original case studies employ insights from anthropology, history, geography, pharmaceutical sciences, botany, and economics to trace the transformation of Asian medical traditions into rapidly growing and dynamic pharmaceutical industries. Collectively, these contributions identify this as a major phenomenon impacting Asian and global healthcare, economics, cultural politics, and environments. The book suggests that we can learn more about Asian medicines today by approaching them as industries rather than as cultural or epistemic systems. Asian Medical Industries is a highly original resource for students and scholars across a range of academic fields such as anthropology, history, and Asian studies, as well as medical practitioners, health sector actors, and policymakers.

The Indian Pharmaceutical Industry
The Indian Pharmaceutical Industry

Author: Yaeko Mitsumori

Publisher: Springer

Published: 2018-06-28

Total Pages: 122

ISBN-13: 9811067902

DOWNLOAD EBOOK

This study analyzes the impact of the revision of the Indian Patent Act (2005) on the Indian pharmaceutical industry, which has been achieving healthy growth over the past 30 to 40 years or more. As of 2005, the Indian pharmaceutical industry was ranked as No. 4 in the world in terms of volume and 15th in terms of value. WTO/TRIPS required India to revise its patent law, however, and to introduce product patents in the pharmaceutical field. Many not only in India but also in the world had argued that the local pharmaceutical industry could deteriorate once a strong patent law (such as a product patent) was introduced. However, the Indian pharmaceutical industry has continued to develop rapidly even after the revision of the patent law in 2005. This present study started with efforts to work out the reason the Indian pharmaceutical industry successfully expanded even after the introduction of product patents. The study found that a unique article (the so-called '3-d‘) inserted in the Patent Act 2005 might have played a role in diminishing or preventing a negative impact from the introduction of a strong patent system, such as a product patents. The study also considers that a change of the business model adopted by the Indian pharmaceutical industry might have contributed to diminishing the effect of the negative impact from the introduction of a strong patent law. This study also covers recent developments in India regarding intellectual property rights and the pharmaceutical industry. One is India’s very first compulsory license granted to an Indian pharmaceutical company, Natco, against the large German pharmaceutical firm Bayer; and the second is the Supreme Court decision on Novartis’ Gleevec. The study analyzes the fundamental problems that caused these two events: access to medicine and gaps in the concept of intellectual property in the pharmaceutical industry. As possible solutions to these fundamental issues, this book explores the ideas of voluntary licensing and tiered pricing.